Briggs Morrison - Jul 1, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President, Head of R&D, Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Stock symbol
SNDX
Transactions as of
Jul 1, 2022
Transactions value $
-$734,927
Form type
4
Date filed
7/5/2022, 04:09 PM
Previous filing
Jun 21, 2022
Next filing
Sep 16, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $449K +62.3K +349.25% $7.20 80.1K Jul 1, 2022 Direct
transaction SNDX Common Stock Sale -$1.18M -62.3K -77.74% $19.00 17.8K Jul 1, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -62.3K -100% $0.00* 0 Jul 1, 2022 Common Stock 62.3K $7.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,200,616 options to purchase shares of common stock that are vested and immediately exercisable and a total of 397,792 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $18.61 to $19.38
F3 This option is fully vested.